РОЛЬ МЕЗЕНХИМАЛЬНЫХ МУЛЬТИПОТЕНТНЫХ СТРОМАЛЬНЫХ КЛЕТОК В РЕМОДЕЛИРОВАНИИ КОСТНОЙ ТКАНИ

Способность мезенхимальных мультипотентных стромальных клеток (МСК) дифференцироваться в несколько видов мезенхимальных тканей делает эти клетки основными кандидатами для создания тканеинженерных конструкций для регенеративной медицины. МСК способствуют интеграции биоимплантата с нативной костью и стимулируют процесс остеогенеза, но также обладают иммуномодулирующими свойствами, контролируя воспалительные реакции и модифицируя иммунные клетки. МСК влияют не только на иммунный ответ организма, препятствуя реакции иммунологического отторжения имплантированных тканеинженерных конструкций, но могут также оказывать воздействие на иммунные реакции костной ткани. MСК играют важную роль в регенерации кости, регулируя образования остеобластов и подавляя активность эффекторов воспаления и остекластогенез. Доклинические и первые клинические испытания биоимплантатов кости, заселенных МСК, свидетельствуют о перспективности данной стратегии получения тканеинженерных конструкций для регенерации костей.

мезенхимальные мультипотентные стромальные клетки, иммуномодулирующая активность, биоимплантаты костей, остеоиммунология, тканеинженерные конструкции

1. Киселевский М.В., Анисимова Н.Ю., Корнюшенков Е.А., Шепелев А.Д., Чвалун С.Н., Полоцкий Б.Е., Давыдов М.И. Биосовместимые синтетические матриксы трахеи на основе полимерных ультраволокнистых материалов, колонизированные мезенхимальными мультипотентными клетками // Современные технологии в медицине, 2016. Т. 8, № 1. C. 7-13. [Kiselevsky M.V., Anisimova N.Yu., Kornushenkov E.A., Shepelev A.D., Chvalun S.N., Polotsky B.E., Davydov M.I. Biocompatible synthetic tracheal matrices based on polymer. Sovremennye tekhnologii v meditsine = Modern Technologies in Medicine, 2016, Vol. 8, no. 1, pp. 7-13. (In Russ.)]

2. Климович В.Б. Иммуномодулирующая активность мезенхимальных стромальных (стволовых) клеток // Медицинская иммунология, 2014. T. 16, № 2. С. 107-126. [Klimovich V.B. Immunomodulatory activity of mesenchimal stromal (stem) cells. Meditsinskaya immunologiya = Medical Immunology (Russia), 2014, Vol. 16, no. 2, pp. 107-126. (In Russ.)] doi: 10.15789/1563-0625-2014-2-107-12.

3. Alcayaga-Miranda F., Cuenca. J,. Martin A., Contreras L., Figueroa F.E., Khour M. Combination therapy of menstrual derived mesenchymal stem cells and antibiotics ameliorates survival in sepsis. Stem Cell Res. Ther., 2015, Vol. 6, no. 6, p. 199.

4. Arck P.C., Hecher K. Fetomaternal immune cross-talk and its consequences for maternal and offspring’s health. Nat. Med., 2013, Vol. 19, no. 5, pp. 548-556.

5. Aubin J. Regulation of osteoblast formation and function. Rev. Endocrinol. Metab. Disord., 2001, Vol. 2, no. 1, pp. 81-94.

6. Bianco P., Cao X., Frenette P.S., Mao J.J., Robey, P.G., Simmons P.J., Wang C.Y. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat. Med., 2013, Vol. 19, no. 1, pp. 35-42.

7. Brandau S., Jakob M., Bruderek K., Bootz F., Giebel B., Radtke S., Mauel K., Jäger M., Flohé S.B., Lang S. Mesenchymal stem cells augment the anti-bacterial activity of neutrophil granulocytes. PLoS ONE, 2014, Vol. 9, e106903. doi: 10.1371/journal.pone.0106903.

8. Bunpetch V., Wu H., Zhang S., Ouyang H.W. From “bench to bedside”: current advancement on large-scale production of mesenchymal stem cells. Stem Cells Dev., 2017, Vol. 26, no. 9, pp. 1662-1673.

9. Carty F., Mahon B.P., English K. The influence of macrophages on mesenchymal stromal cell therapy: Passive or aggressive agents? Clin. Exp. Immunol., 2012, Vol. 188, no. 1, pp. 1-11.

10. Cerdeira A.S., Rajakumar A., Royle C.M., Lo A., Husain Z., Thadhani R.I., Sukhatme V.P., Karumanchi S.A., Kopcow H.D. Conversion of peripheral blood NK cells to a decidual NK-like phenotype by a cocktail of defined factors. J. Immunol., 2013, Vol. 190, no. 8, pp. 3939-3948.

11. Chena F-M., Liu X. Advancing biomaterials of human origin for tissue engineering. Prog. Polym. Sci., 2016. Vol. 53, no. 1, pp. 86-168.

12. Cheng J., Liu J., Shi Z., Jules J., Xu D., Luo S., Wei S., Feng X. Molecular mechanisms of the biphasic effects of interferon-γ on osteoclastogenesis. J. Interferon Cytokine Res., 2012, Vol. 32, no. 1, pp. 34-45.

13. Croes M., Oner F.C., Kruyt M.C., Blokhuis T.J., Bastian O., Dhert W.J., Alblas J. Proinflammatory mediators enhance the osteogenesis of human mesenchymal stem cells after lineage commitment. PloS ONE, 2015, Vol. 10, no. 7, e0132781. doi: 10.1371/journal.pone.0132781.

14. Сornish J., Gillespi M.T., Callon K.E., Horwood N.J., Moseley J.M., Reid I.R. Interleukin-18 is a novel mitogen of osteogenic and chondrogenic cells. Endocrinology, 2005, Vol. 144, no. 4, pp. 1194-1201.

15. Dawson J.I., Oreffo R.O. Bridging the regeneration gap: stem cells, biomaterials and clinical translation in bone tissue engineering. Arch. Biochem. Biophys., 2008, Vol. 473, no. 2, pp. 124-131.

16. Dayan V., Yannarelli G., Billia F., Filomeno P., Wang X.H., Davies J.E., Keating A. Mesenchymal stromal cells mediate a switch to alternatively activated monocytes/macrophages after acute myocardial infarction. Basic Res. Cardiol., 2011, Vol. 106, no. 6, pp. 1299-1310.

17. Discher D.E., Mooney D.J., Zandstra P.W. Growth factors, matrices, and forces combine and control stem cells. Science, 2009, Vol. 324, no. 5935, pp. 1673-1677.

18. Eggenhofer E., Hoogduijn M.J. Mesenchymal stem cell-educated macrophages. Transplant. Res., 2012, Vol. 1, no. 1, pp. 1-12.

19. Feinberg A.W. Engineered tissue grafts: opportunities and challenges in regenerative medicine. Wiley Interdiscip. Rev. Syst. Biol. Med., 2012, Vol. 4, no. 2, pp. 207-220.

20. Fisher M.B., Mauck R.L. Tissue engineering and regenerative medicine: recent innovations and the transition to translation. Tissue Eng. Part B Rev., 2013, Vol. 19, no. 1, pp. 1-13.

21. Galland S., Vuille J., Martin P., Letovanec I. Tumor-derived mesenchymal stem cells use distinct mechanisms to block the activity of natural killer cell subsets. Cell Rep., 2017, Vol. 20, no. 12, pp. 2891-2905.

22. Gao F., Chiu S.M., Motan D.A., Zhang Z., Chen L., Ji H.L., Zhang Z., Chen L., Ji H.L., Tse H.F., Fu Q.L., Lian Q. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis., 2016, Vol. 21, no. 7, e2062. doi: 10.1038/cddis.2015.327.

23. Griffith L.G., Naughton G. Tissue engineering – current challenges and expanding opportunities. Science, 2002, Vol. 295, no. 5556, pp. 1009-1014.

24. Guarino V., Causa F., Ambrosio L. Bioactive scaffolds for bone and ligament tissue. Expert. Rev. Med. Devices, 2007, Vol. 4, no. 3, pp. 405-418.

25. Hanker J.S., Giammara B.L. Biomaterials and biomedical devices. Science, 1988, Vol. 242, no. 4880, pp. 885-892.

26. Hanson S., D’Souza R.N., Hematti P. Biomaterial-mesenchymal stem cell constructs for immunomodulation in composite tissue engineering. Tissue Eng. Part A, 2014, Vol. 20, no. 15-16, pp. 2162-2168.

27. Hardy J.G., Villancio-Wolter M.K., Sukhavasi R.C., Mouser D.J., Aguilar D. Jr, Geissler S.A., Kaplan D.L., Schmidt C.E. Electrical stimulation of human mesenchymal stem cells on conductive nanofibers enhances their differentiation toward osteogenic outcomes. Macromolecular Rapid Communications, 2015, Vol. 36, no. 1, pp. 1884-1890.

28. Harrison R.H., St-Pierre J.P., Stevens M.M. Tissue engineering and regenerative medicine: a year in review. Tissue Eng. Part B Rev., 2014, Vol. 20, no. 1, pp. 1-16.

29. Liu D., Yi C., Fong C.C., Jin Q., Wang Z., Yu W.K., Sun D., Zhao J., Yang M. Activation of multiple signaling pathways during the differentiation of mesenchymal stem cells cultured in a silicon nanowire microenvironment. Nanomed, 2014, Vol. 10, no. 6, pp. 1153-1163.

30. Johnson V., Webb T., Norman A., Coy J., Kurihara J., Regan D., Dow S. Activated mesenchymal stem cells interact with antibiotics and host innate immune responses to control chronic bacterial infections. Sci. Rep., 2017, Vol. 7, no. 1, p. 9575.

31. Katagiri W., Osugi M., Kawai T., Hibi H. First-in-human study and clinical case reports of the alveolar bone regeneration with the secretome from human mesenchymal stem cells. Head Face Med., 2016, Vol. 12, no. 5, pp. 1-10.

32. Kiernan C.H., Wolvius E.B., Brama P.A.J., Farrell E. The immune response to allogeneic differentiated mesenchymal stem cells in the context of bone tissue engineering. Tissue Eng. Part B Rev., 2018, Vol. 24, no. 1, pp. 75-83.

33. Krasnodembskaya A., Song Y., Fang X., Gupta N., Serikov V., Lee J.W., Matthay M.A. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells, 2010, Vol. 28, no. 25, pp. 2229-2238.

34. Lee K., Silva E.A., Mooney D.J. Growth factor delivery-based tissue engineering: general approaches and a review of recent developments. J. R. Soc. Interface, 2011, Vol. 8, no. 55, pp. 153-170.

35. Li M., Hasegawa T., Hogo H., Tatsumi S., Liu Z., Guo Y., Sasaki M., Tabata C., Yamamoto T., Ikeda K., Amizuka N. Histological examination on osteoblastic activities in the alveolar bone of transgenic mice with induced ablation of osteocytes. Histol. Histopathol., 2013, Vol. 28, no. 3, pp. 327-335.

36. Lin G.L., Hankenson K.D. Integration of BMP, Wnt, and notch signaling pathways in osteoblast differentiation. J. Cell Biochem., 2011, Vol. 112, no. 12, pp. 3491-3501.

37. Liu H., Kemeny, D.M., Heng B.C., Ouyang H.W., Melendez A.J., Cao T. The immunogenicity and immunomodulatory function of osteogenic cells differentiated from mesenchymal stem cells. J. Immunol., 2006, Vol. 176, no. 5, pp. 2864-2871.

38. Liu W.H., Liu J.J., Wu J., Zhang L.L., Liu F., Yin L., Zhang M.M., Yu B. Novel mechanism of inhibition of dendritic cells maturation by mesenchymal stem cells via interleukin 10 and the JAK1/STAT3 signaling pathway. PLoS ONE, 2013, Vol. 38, no. 1, e55487. doi: 10.1371/journal.pone.0055487.

39. Lu W., Fu C., Song L., Yao Y., Zhang X., Chen Z., Li Y., Ma G., Shen C. Exposure to supernatants of macrophages that phagocytized dead mesenchymal stem cells improves hypoxic cardiomyocytes survival. Int. J. Cardiol., 2012, Vol. 165, no. 2, pp. 333-340.

40. Luk F., Carreras-Planella L., Korevaar S.S. Inflammatory conditions dictate the effect of mesenchymal stem or stromal cells on b cell function. Front. Immunol., 2017, Vol. 8, 1042. doi: 10.3389/ mmu.2017.01042.

41. Mukonoweshuro B., Brown C.J., Fisher J., Ingham E. Immunogenicity of undifferentiated and differentiated allogeneic mouse mesenchymal stem cells. J. Tissue Eng., 2014, Vol. 5, no. 1, pp. 1-15.

42. Neuss S., Denecke B., Gan L., Lin Q. Transcriptome analysis of MSC and MSC-derived osteoblasts on resomer® Lt706 and Pcl: impact of biomaterial substrate on osteogenic differentiation. PLoS ONE, 2011, Vol. 6, no. 9, e23195. doi: 10.1371/journal.pone.0023195.

43. New S.E., Ibrahim A., Guasti L. Towards reconstruction of epithelialized cartilages from autologous adipose tissue-derived stem cells. J. Tissue Eng. Regen. Med., 2016, Vol. 11, no. 11, pp. 3078-3089.

44. Niaza K., Senatov F., Anisimova N., Kiselevskiy M., Kaloshkin S. Effect of co-incubation with mesenchymal stromal cells in cultural medium on structure and mechanical properties of polylactide-based scaffolds. BioNano Science, 2017, Vol. 7, no. 4, pp. 712-717.

45. Nich C., Takakubo Y., Pajarinen J., Ainola M., Salem A., Sillat T., Rao A.J., Raska M., Tamaki Y., Takagi M., Konttinen Y.T., Goodman S.B., Gallo J. Macrophages-key cells in the response to wear debris from joint replacements. J. Biomed. Mater. Res. A, 2013, Vol. 101, no. 10, pp. 3033-3045.

46. Petri R.M., Hackel A., Hahnel K., Dumitru C.A., Bruderek K., Flohe S.B., Paschen A., Lang S., Brandau S. Activated tissue-resident mesenchymal stromal cells regulate natural killer cell immune and tissue-regenerative function. Stem Cell Reports, 2017, Vol. 9, pp. 985-998.

47. Raggatt L.J., Partridge N.C. Cellular and molecular mechanisms of bone remodeling. J. Biol. Chem., 2010, Vol. 285, no. 33, pp. 25103-25108.

48. Raicevic G., Najar M., Najimi M., El Taghdouini A., van Grunsven L.A., Sokal E., Toungouz M. Influence of inflammation on the immunological profile of adult-derived human liver mesenchymal stromal cells and stellate cells. Cytotherapy, 2015, Vol. 17, no. 2, pp. 174-185.

49. Rauner M., Sipos W., Pietschmann P. Osteoimmunology. Int. Arch. Allergy Immunol., 2007, Vol. 143, no. 1, pp. 31-48.

50. Roszer T. Understanding the Mysterious M2 macrophage through activation markers and effector mechanisms. Mediators Inflamm., 2015, Vol. 2015, no. 1, pp. 1-16.

51. Santo V.E., Gomes M.E., Mano J.F., Reis R.L. Controlled release strategies for bone, cartilage, and osteochondral engineering – Part I: recapitulation of native tissue healing and variables for the design of delivery systems. Tissue Eng. Part B Rev., 2013, Vol. 19, no. 4, pp. 308-326.

52. Senatov F.S., Zadorozhnyy M.Yu., Niaza K.V., Medvedev V.V., Kaloshkin S.D., Anisimova N.Yu., Kiselevskiy M.V., Yang K-C. Shape memory effect in 3D-printed scaffolds for self-fitting implants. Eur. Polymer J., 2017, Vol. 93, no. 1, pp. 222-231.

53. Soto-Gutierrez A., Wertheim J.A., Ott H.C., Gilbert T.W. Perspectives on whole-organ assembly: moving toward transplantation on demand. J. Clin. Invest., 2012, Vol. 122, no. 11, pp. 3817-3823.

54. Sutton M.T., Fletcher D., Ghosh S.K., Weinberg A., van Heeckeren R., Kaur S., Sadeghi Z., Hijaz A., Reese J., Lazarus H.M., Lennon D.P., Caplan A.I., Bonfield T.L. Antimicrobial properties of mesenchymal stem cells: therapeutic potential for cystic fibrosis infection, and treatment. Stem Cells Int., 2016, Vol. 2016, no. 1, pp. 1-12.

55. Wang M.L., Nesti L.J., Tuli R., Lazatin J., Danielson K.G., Sharkey P.F., Tuan R.S. Titanium particles suppress expression of osteoblastic phenotype in human mesenchymal stem cells. J. Orthop. Res., 2002, Vol. 20, no. 6, pp. 1175-1184.

56. Xue R., Qian Y., Li L., Yao G., Yang L., Sun Y. Polycaprolactone nanofiber scaffold enhances the osteogenic differentiation potency of various human tissue-derived mesenchymal stem cells. Stem Cell Res. Ther., 2017, Vol. 8, no. 1, p. 148.

57. Yagi H., Soto-Gutierrez A. Parekkadan B., Kitagawa Y, Tompkins R.G., Kobayashi N., Yarmush M.L. Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplant., 2010, Vol. 19, no. 6, pp. 667-679.

58. Zhang S., Chen X., Hu Y., Wu J., Cao Q. Chen S., Gao Y. All-trans retinoic acid modulates Wnt3A-induced osteogenic differentiation of mesenchymal stem cells via activating the PI3K/AKT/GSK3beta signalling pathway. Mol. Cell. Endocrinol., 2016, Vol. 42, no. 422, pp. 243-253.

59. Zhou Y., Tsai T.L., Li W.J. Strategies to retain properties of bone marrow-derived mesenchymal stem cells ex vivo. Ann. N. Y. Acad. Sci., 2017, Vol. 1409, no. 1, pp. 3-17.

60. Zimmermann J.A., Hettiaratchi M.H., McDevitt T.C. Enhanced Immunosuppression of T cells by sustained presentation of bioactive interferon-γ within three-dimensional mesenchymal stem cell constructs. Stem Cells Transl. Med., 2017, Vol. 6, no. 1, pp. 223-237.